Akina Pharmacy (Northern VA Compounders PLLC), Sterling, VA
Is Akina Pharmacy (Northern VA Compounders PLLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Akina Pharmacy (Northern VA Compounders PLLC) hold a Virginia pharmacy license?
State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions. The Colorado State Board of Pharmacy also lists nonresident license OSP 6481 for Akina Pharmacy, Sterling, VA, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054019459 for NORTHERN VA COMPOUNDERS LLC, STERLING, VA, status INOPERATIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003070 for AKINA PHARMACY, Sterling, VA, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001360 for Akina Pharmacy, STERLING, VA, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301014016 for NORTHERN VA COMPOUNDERS PLLC, Sterling, VA, status Active, as of Nov 10, 2026.
Has Akina Pharmacy (Northern VA Compounders PLLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Apr 12, 2024) for Akina Pharmacy (Northern VA Compounders PLLC). State board actions: no Virginia Board of Pharmacy action under this exact name and city was found in the Virginia Department of Health Professions’ list of Board of Pharmacy case decisions from the last 90 days (actions dated Aug 17, 2026 to Nov 15, 2026) on Nov 15, 2026. The Colorado State Board of Pharmacy’s license dataset also lists 5 actions: “CLS Stipulation” dated Sep 5, 2024, case 2024-2786 on nonresident license OSP 6481, “CLS Stipulation” dated Feb 1, 2023, case 2022-7704 on nonresident license OSP 6481 and “CLS Stipulation” dated Apr 8, 2022, case 2021-7807 on nonresident license OSP 6481, and more listed below.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Northern VA Compounders PLLC; Akina Pharmacy
- Location
- Sterling, VA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Apr 12, 2024
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 9 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Northern VA Compounders PLLC, (dba Akina Pharmacy), a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Apr 12, 2024 | Warning letter | Warning Letter Issued 04/12/2024 | fda.gov |
| Dec 9, 2022 | Form 483 | 483 Issued 12/09/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Northern VA Compounders PLLC, Sterling, VA (FEI number 3012590153), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 9, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3012590153 | 1192369 |
Form 483s FDA has published for this site
- Dec 9, 2022: Form 483 to Northern VA Compounders PLLC, published Feb 21, 2023. fda.gov
- Sep 12, 2016: Form 483 to Northern VA Compounders PLLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 7, 2022 to Dec 9, 2022: 9 observations
- Firm on the cover
- Northern VA Compounders PLLC, 23475 Rock Haven Way, Suite 105, Sterling, VA 20166-4444
- FEI number
- 3012590153
- Establishment type on the cover
- Producer of Steril e Drugs
- FDA district office on the cover
- 11155 Dolfield Boulevard, Suite 117 Owi ngs Mills, MD 21117
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced beta-lactam drugs without providing adequate containment, segregation, cleaning of work surfaces, cleaning of utensils and cleaning of personnel to prevent cross-contamination.
Specifically, you produced beta-lactam drug products in the non-sterile, non-hazardous compounding room <Redacted B4> of your facility on the same day you produced non-beta lactam drug products. Your records do not indicate if the beta-lactam drugs were conta.ined or segregated from non-beta lactam drug products during production. Your cleaning records indicate that you only cleaned the <Redacted B4> compounding foods and work surfaces with <Redacted B4> and <Redacted B4> and have not determined that this cleaning method is adequate to prevent cross containination between the beta-lactam drug products and non-beta-lactam drug products. ...
Observation 2
The <Redacted B4> intended to render fmal product sterile was not pharmaceutical grade.
Specifically, you use <Redacted B4> sterile <Redacted B4> Catalogue Number <Redacted B4> your drug products. The information you provided does not show that the <Redacted B4>. Catalogue Number <Redacted B4> is a pharmaceutical grade <Redacted B4>. A review of the information available on the manufacture's website shows the <Redacted B4> is for "research use only." On 10/24/2022, you used a <Redacted B4> Hyaluronic Acid Sodium Salt/Lidocaine HCI 11MG/10MG/ML Injectable, Lot# 10242022@ <Redacted B4>.
Observation 3
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
• You use non-pharmaceutical grade <Redacted B4> as an ingredient in the production of non-sterile drug products and cleaning of utensils and glassware utilized in non-sterile drug production.
• You do not perform analytical or microbiological testing of this <Redacted B4> generated through your <Redacted B4>. This <Redacted B4> is used in the production of non-sterile drug products.
Observation 4
The ISO 5 classified aseptic processing areas had difficult to clean, particle-generating and visibly dirty equipment or surface.
Specifically, during the inspection the following deficiencies were observed in the sterile compounding areas of the fnm's compounding suite.
• On 11/11/2022, two fluorescent lights fixtures were observed mounted on the rear <Redacted B4> surface inside the ISO 5 <Redacted B4> 'LFH located in the non-hazardous, ISO 7 Buffer Room <Redacted B4> which have hard to clean surfaces. The bottom fluorescent light fixture mounted inside the ISO 5 OLFH was observed to have an unknown black substance on the bottom front face of the light fixture.
• During production operations on l l/07/2022 and 11/08/2022, a white "adhesive substance" was observed on the plexiglass sash of the ISO 5 <Redacted B4> 'LFH located in the non-hazardous, ISO 7 Buffer Room <Redacted B4>
• During production operations on l l/07/2022, the compounding operator was observed filling vials of drug product inside the ISO 5 LJLFH located in the non-hazardous, ISO 7 Buffer Room <Redacted B4> using white and blue plastic trays with difficult to clean surfaces. ...
Observation 5
You produced hazardous drugs without providing adequate cleaning of work surfaces to prevent cross-contamination.
Specifically, on 11/14/2022, visible white residue was observed in the <Redacted B4> Biological Safety Cabinets located in the unclassified hazardous, non-sterile room <Redacted B4>, immediately after you performed <Redacted B4> cleaning of the room and equipment. White residue was observed inside each hood at the corners where the <Redacted B4> interior surfaces meet the <Redacted B4> work surface. A layer of dust and a white powdery substance was observed in the air exhaust space inside the top section of each compounding hood and on each <Redacted B4> located inside the air exhaust space. A white powdery substance was also observed along the surfaces located outside each compounding hood, with a higher concentration observed outside holes in the <Redacted B4> sides of each hood.
Observation 6
Non-microbial contamination was observed in your production area.
Specifically,
• On 11/11/2022, during a walk-through of the sterile compounding rooms, chipping paint was observed above the doorknob on the door face located inside the hazardous, ISO 7 Anteroom <Redacted B4>
• On 11/10/202, during the production of <Redacted B4> Topical (Lipodenn EQ) 23~/6%/4% Cream lot 11102022@ <Redacted B4> in the non-sterile, non-hazardous compounding_room <Redacted B4> we observed the Pharmacy Technician use the ointment mill located in room <Redacted B4> that had paint chipping adjacent to the rollers, which are product contact surfaces.
• On 11/15/2022, during the production of Estradiol lmg/gm (0.1 % ) cream lot 11152022@ <Redacted B4> in the non-sterile, hazardous room <Redacted B4>, we observed the Pharmacy Technician use the ointment mill located in room <Redacted B4> that had paint chipping adjacent to the rollers, which are product contact surfaces.
Observation 7
Personnel conducted aseptic manipulations and placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.
Specifically, on 11/07/2022, a Pharmacy Technician was observed producing Trimix Original (PG/PAP/PT), Lot# 11072022@ <Redacted B4> in the ISO 5 <Redacted B4> LFH located in the non-hazardous, ISO 7 Buffer Room <Redacted B4>. During production, the operator was observed filling vials with drug product using a <Redacted B4> syringe. During filling, the operator placed her hand directly above a tray of empty and filled sterile vials which blocked first pass air from the HEP A filter above the open vials.
Observation 8
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, on 11/08/2022a Pharmacy Technician was observed performing gowning in the non-11 hazardous, ISO 7 Anteroom <Redacted B4>. While donning gowning materials, the technician was observed using the thumb of her sterile gloved hands to push the sleeves of her sterile gown under the cuff of the sterile glove on the opposite hand. This was done when she donned sterile gloves before performing <Redacted B4> cleaning in the non-hazardous ISO 7 Anteroom <Redacted B4> and ISO 7 Buffer Room <Redacted B4> and when she changed her gloves immediately prior to performing production operations in the non-hazardous, ISO 7 Anteroom <Redacted B4> and non-hazardous, ISO 7 Buffer Room <Redacted B4>.
Observation 9
You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.
Specifically, you conducted air pattern analyses (smoke studies) in December 2021 and June 2022 for the ISO 5 Biological Safety Cabinet (BSC) used to produce hazardous, sterile drug products and the ISO 5 <Redacted B4> Laminar Flow Hood Q LFH) used to produce non-hazardous, sterile drug products. The smoke studies performed were deficient:
The 12/2021 and 06/2022 studies for the BSC and LFH did not include the transfer of all starting components and materials into the ISO 5 classified areas and failed to include all manipulations and transfers performed by _the operator during production. In addition, the smokes studies performed in the BSC and <Redacted B4> LFH failed to simulate the most complex products produced in the BSC <Redacted B4> LFH which the firm identified as Bimix Intracavemosal Injection Solution, Trimix Intracavemosal Injection Solution, Quadinix Intracavemosal Injection Solution, and Atropine Ophthalmic Solution. ...
Linked 483s whose text is not shown
- Sep 12, 2016: FDA document 100574: the PDF is a scanned image with no readable text.
State board of pharmacy records
State pharmacy license records for Virginia are not checked: the Department of Health Professions’ license lookup is an interactive search form, which this index does not use. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Pharmacy case decisions the Department of Health Professions lists as entered in the last 90 days, worded as it gives them. Older decisions are reachable only through a search form, which this index does not use, so only that 90-day window is checked. The orders themselves sit behind a disclaimer form and are not linked. Virginia pharmacy licenses are not checked. Actions in the data are dated Aug 17, 2026 to Nov 15, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6481 | OSP | Akina Pharmacy | Sterling, VA | Active |
- Sep 5, 2024: “CLS Stipulation”, license OSP 6481, case 2024-2786, Akina Pharmacy, Sterling, VA. Board document
- Feb 1, 2023: “CLS Stipulation”, license OSP 6481, case 2022-7704, Akina Pharmacy, Sterling, VA. Board document
- Apr 8, 2022: “CLS Stipulation”, license OSP 6481, case 2021-7807, Akina Pharmacy, Sterling, VA. Board document
- May 6, 2021: “CLS Stipulation”, license OSP 6481, case 2021-136, Akina Pharmacy, Sterling, VA. Board document
- Jan 6, 2020: “CLS Letter of Admonition”, license OSP 6481, case 2019-5793, Akina Pharmacy, Sterling, VA. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054019459 | LICENSED PHARMACY | NORTHERN VA COMPOUNDERS LLC | STERLING, VA | INOPERATIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0003070 | NONRESIDENT PHARMACY | AKINA PHARMACY | Sterling, VA | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0001360 | Non Resident Pharmacy | Akina Pharmacy | STERLING, VA | Active |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301014016 | Pharmacy | NORTHERN VA COMPOUNDERS PLLC | Sterling, VA | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Virginia Board of Pharmacy disciplinary records
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.